Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.
Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.
Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.
Akero Therapeutics (Nasdaq: AKRO) has completed enrollment in its Phase 2b HARMONY study for efruxifermin (EFX), targeting non-alcoholic steatohepatitis (NASH). This follows promising Phase 2a results where 48% of patients showed fibrosis improvement after 16 weeks. The Phase 2b trial involves a longer 24-week treatment period, aiming for fibrosis regression. Preliminary results are expected in Q3 2022. EFX is designed for convenient dosing and may become a leading NASH treatment if proven effective.
Akero Therapeutics (Nasdaq: AKRO) announced its participation at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 10:30 a.m. E.T. The live presentation will be accessible via the investor relations section of their website, with archived replays available afterward.
Akero is focused on developing therapies for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). Their lead candidate, efruxifermin (EFX), is undergoing Phase 2b trials and aims to provide a groundbreaking treatment option for patients.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2 at 3:30 p.m. E.T. This event will include a management fireside chat, which will be accessible via a live webcast on the company's investor relations page. Akero Therapeutics focuses on developing treatments for serious metabolic diseases, specifically targeting non-alcoholic steatohepatitis (NASH). Its lead candidate, efruxifermin (EFX), is currently undergoing two Phase 2b trials aimed at assessing its effectiveness in various patient groups.
On November 12, 2021, Akero Therapeutics (Nasdaq: AKRO) reported promising results from a post-hoc analysis of its Phase 2a BALANCED study of efruxifermin (EFX) for non-alcoholic steatohepatitis (NASH). After 16 weeks, 87% (35 of 40) of EFX-treated patients showed improvements in steatohepatitis, while 80% (32 of 40) demonstrated fibrosis improvement. The findings were presented at The Liver Meeting of the American Association for the Study of Liver Diseases. Akero is optimistic about the upcoming Phase 2b studies and the potential for EFX to become a leading treatment for NASH.
Akero Therapeutics (AKRO) reported its Q3 2021 financial results, highlighting a cash position of $215.1 million, sufficient to fund operations into Q3 2023. The company is progressing in two Phase 2b clinical trials for efruxifermin (EFX) targeting non-alcoholic steatohepatitis (NASH). Notably, the FDA granted Fast Track designation for EFX, enabling more frequent interactions and potential priority review. Q3 research and development expenses increased to $19.5 million, with total operating expenses at $24.4 million, compared to $21.5 million in Q3 2020.
Akero Therapeutics (Nasdaq: AKRO) announced participation in a fireside chat at the Jefferies London Healthcare Conference, available for on-demand viewing on November 18 at 3:00 a.m. EST. Known for its focus on serious metabolic diseases, Akero is developing efruxifermin (EFX), a potential best-in-class treatment for non-alcoholic steatohepatitis (NASH), which currently lacks approved therapies. EFX is undergoing evaluation in two Phase 2b trials: HARMONY and SYMMETRY.
Akero Therapeutics (NASDAQ: AKRO) announced that the FDA has granted Fast Track designation for its lead program, efruxifermin (EFX), aimed at treating non-alcoholic steatohepatitis (NASH). This designation facilitates quicker development and potential priority review of the drug. Currently, EFX is in two Phase 2b clinical trials targeting advanced fibrosis and cirrhosis in NASH patients. The company reported promising clinical data, including a 50% improvement in fibrosis for half of F2/F3 patients. NASH is expected to affect 27 million Americans by 2030, with no approved therapies available.
Akero Therapeutics (Nasdaq: AKRO) announced that Tim Rolph, Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 12:00 p.m. (ET). The presentation will be available via a live webcast on the company's investor relations website. Akero is focused on developing treatments for non-alcoholic steatohepatitis (NASH), with its lead candidate, efruxifermin (EFX), currently undergoing a Phase 2b clinical trial. EFX offers a promising treatment approach for this complex disease.
Akero Therapeutics (Nasdaq: AKRO) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2021, at 11:45 a.m. (ET). The presentation will highlight the company's innovative approach to treating non-alcoholic steatohepatitis (NASH) with its investigational drug, efruxifermin (EFX). EFX aims to offer potential benefits as a best-in-class medicine, with ongoing Phase 2b trials evaluating its effectiveness in patients with varying fibrosis stages. A live webcast of the presentation will be available on Akero's investor relations website.
Akero Therapeutics (Nasdaq: AKRO) reported its Q2 2021 financial results, highlighting the ongoing development of efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH). The company has initiated a second Phase 2b clinical trial for late-stage cirrhotic NASH patients, following significant progress in previous trials, including a published study demonstrating fibrosis regression. As of June 30, 2021, Akero's cash and marketable securities totaled $230 million, expected to support operations through Q3 2023. R&D expenses rose to $24 million, reflecting increased costs related to EFX programs.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
